Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Other Operating Expenses data on file, last reported at $454000.0 in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 156.5% year-over-year to $454000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 159.15% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 125.3% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $454000.0, up from $442000.0 in the prior quarter.
• Over the last five years, Other Operating Expenses for VVOS reached as high as $454000.0 in Q1 2026 and fell as low as $144000.0 in Q4 2024.
• Historically, Other Operating Expenses has averaged $213764.7 across 5 years, with a median of $162000.0 in 2022.
• Across the five-year window, Other Operating Expenses slumped 84.34% in 2022 and soared 206.94% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $169000.0 in 2022, then dropped by 11.83% to $149000.0 in 2023, then retreated by 3.36% to $144000.0 in 2024, then surged by 206.94% to $442000.0 in 2025, then advanced by 2.71% to $454000.0 in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $454000.0 in Q1 2026, $442000.0 in Q4 2025, and $384000.0 in Q3 2025.